Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive DyskinesiaPRNewsWire • 11/08/23
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023PRNewsWire • 11/02/23
Neurocrine (NBIX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/31/23
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales GuidancePRNewsWire • 10/31/23
Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The SuccessSeeking Alpha • 10/11/23
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial ResultsPRNewsWire • 10/10/23
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary EndpointsPRNewsWire • 10/05/23
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023PRNewsWire • 09/21/23
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle FormulationPRNewsWire • 09/14/23
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?Investors Business Daily • 09/12/23
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)PRNewsWire • 09/12/23
Sosei Heptares' partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy AdultsGlobeNewsWire • 09/11/23
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy AdultsPRNewsWire • 09/11/23
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) CapPRNewsWire • 08/29/23
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's DiseasePRNewsWire • 08/28/23
Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do ItSeeking Alpha • 08/25/23
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatmentMarket Watch • 08/21/23
Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's DiseasePRNewsWire • 08/18/23